Walt Disney Co vs Heron Therapeutics Inc — how do they compare? Walt Disney Co trades at $103.37 (market cap $178.16B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Walt Disney Co is far larger — about 2809.7× Heron Therapeutics Inc's market cap, and Walt Disney Co pays a 1.45% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DIS | HRTX | |
|---|---|---|
Market Cap | $178.16B | $63.41M |
Volume | 7,546,013 | — |
Sector | Media | Health |
52-Week High | $118.86 | $1.49 |
52-Week Low | $92.40 | $0.32 |
Enterprise Value | $219.02B | $161.31M |
Dividend Yield | 1.45% | — |
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $103.51, down 1.32% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with four consecutive quarterly earnings beats, revenue growth to $94.43B in 2025, and improving profit margins. Recent news highlights advertising opportunities from major events and ongoing FCC regulatory challenges.
Outlook remains positive with analyst consensus target of $126 representing 22% upside potential. Key opportunities include streaming growth and theme park investments, while risks involve regulatory disputes and box office performance variability. Wall Street maintains strong buy sentiment with 62.5% of analysts recommending purchase.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →